Results 171 to 180 of about 25,999 (347)
Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant‐Ineligible Newly Diagnosed Myeloma: An Australian Real‐World, Multicenter Study
Asia-Pacific Journal of Clinical Oncology, EarlyView.RVD with weekly bortezomib dosing in real‐world newly diagnosed transplant‐ineligible myeloma shows comparable efficacy and reduced toxicity compared to twice‐weekly trial protocols. ABSTRACT Background
Lenalidomide, bortezomib, and dexamethasone (RVD) remains a standard of care regimen for newly diagnosed multiple myeloma in centers without access to ...Samantha Kurniawan, Angela Hwang, Nicole Wong Doo, Tracy King, Christian Bryant, Jennifer Zhang, Kristina Whelan, Parisa Fani‐Molky, Giselle Kidson‐Gerber, Annmarie Bosco, Nada Hamad, Gurdeep Parmar, Fiona Kwok, Sam Lai, Silvia Ling, P. Joy Ho, Georgia McCaughan, Adam Bryant +17 morewiley +1 more sourceIMMU-13. TUMOR INFLAMMATION-ASSOCIATED NEUROTOXICITY (TIAN): A TOXICITY SYNDROME IN PATIENTS TREATED WITH IMMUNOTHERAPY FOR CENTRAL NERVOUS SYSTEM TUMORS [PDF]
Jasia Mahdi, Jörg Dietrich, Karin Straathof, Claire Roddie, Brian J. Scott, Tom B. Davidson, Laura M. Prolo, Tracy T. Batchelor, Cynthia Campen, Kara L. Davis, Juliane Gust, Michael Lim, Robbie G. Majzner, Julie R. Park, Sonia Partap, Sneha Ramakrishna, Rebecca M. Richards, Liora M. Schultz, Nicholas A. Vitanza, Leo D. Wang, Crystal L. Mackall, Michelle Monje +21 moreopenalex +1 more sourceRole for Complement C5 in Eosinophilic Inflammation of Severe Asthma
Allergy, EarlyView.Complement activation module, particularly C5, is positively associated with eosinophilic inflammation in severe asthma cohorts. Elevated C5 expression correlates with poor lung function improvement and persistent eosinophilic inflammation. Mouse model studies confirm that C5 exacerbates eosinophilic inflammation, highlighting its potential as a ...Cong Dong, Shaohua Lu, Zhenan Deng, Xuliang Cai, Huahao Shen, Guochao Shi, Changxing Ou, Zuofu Peng, Wei Jiang, Xiuhua Fu, Changzheng Wang, Meiling Jin, Zhongmin Qiu, Xiaoyang Wei, Wei Gu, Kewu Huang, Qiang Li, Xiangyan Zhang, Nanshan Zhong, Kian Fan Chung, Qingling Zhang, on behalf of C‐BIOPRED Consortium, Jiangtao Lin, Yongming Zhang, Nan Su, Xiaoyan Zhang, Qing Zhao, Ying Nong, Ping Chen, Tianyi Zhu, Binbin Ji, Yan Wang, Haitao Zhao, Jinbao Wang, Zhiyuan Zhang, Xiaona Yang, Chunhua Wei, Jing Han, Nong Yu, Qiang Li, Zhifu Yang, Yanhong Liu, Guohua Li, Huadong Guan, Shuping Zhang, Xiuhua Fu, Lihong Wang, Lingxin Meng, Zhenting Sun, Guangqin Cao, Lei Zhao, Kewu Huang, Hong Zhang, Wen Wang, Li An, Yangyu Chen, Yanli Gao, Xiaoxia Liu, Huifen Zhai, Fang Lin, Zhaohui Zhong, Zhongguang Wen, Yan Xiao, Jian Kang, Linfei Kong, Xinming Su, Xue Yan, Dijia Zhou, Huaping Tang, Wei Han, Yi Shu, Tintian Li, Lixin Xie, Hong Hu, Bo Liu, Yuzhu Li, Longmei Fan, Yue Zhang, Shifeng Zhao, Xiaofang Liu, Yuhong Wang, Xichun Zhang, Xinmao Wang, Pen Bai, Guangfa Wang, Yan Hu, Zhanwei Hu, Ju Cao, Bei He, Rui Wu, Xiaoyan Gai, Hong Zhu, Zhihai Han, Jiyi Meng, Wei Chen, Li Ma, Zhenqian Liu, Chunyang Zhang, Yan Zhang, Huahao Shen, Fugui Yan, Bin Shen, Xinghong Wang, Hao Zhang, Yinghua Yin, Jinkai Liu, Yanxiong Mao, Mao Huang, Xin Yao, Mao Huang, Ji Zhou, Zhenzhen Wu, Ping Yan, Yujie Zhang, Xinling Yang, Ningfei Ji, Fan Fei, Wanzhen Fu, Yi Yang, Yuting Shi, Wangjian Cha, Guochao Shi, Min Zhou, Wei Tang, Wei Chen, Jun Zhou, Wenjie Yang, Lei Zhu, Meiling Jin, Liping Xue, Li Li, Chun Li, Yin Gong, Qiang Li, Guogang Xie, Luhong Bao, Wuping Bao, Nianyun Li, Fengming Ding, Min Zhang, Zhongmin Qiu, Li Yu, Jungang Xie, Lingling Yi, Xianghuai Xu, Qiang Chen, Junjun Tang, Jinfu Xu, Xiaobing Ji, Jingyun Shi, Bo Su, Xiaojun Yang, Jiuwen Bai, Shuo Liang, Kebing Cheng, Wei Gu, Jiyong Ma, Yun Liu, Jun Ren, Shan Mao, Qingling Zhang, Baoqing Sun, Jiaxing Xie, Rihuang Qiu, Zhiqiang Wang, Peiyan Zhen, Wenting Luo, Changgao Zhong, Wei Luo, Yanqing Xie, Xinxin Yu, Wenting Yu, Wei He, Changzheng Wang, Qianli Ma, Min Wan, Mingzhou Zhang, Haining Li, Shaoxi Cai, Haijin Zhao, Yanmei Ye, Fang Zhou, Laiyu Liu, Guohua Huang, Jianpeng Liang, Jianping Zhao, Jungang Xie, Qiongjie Hu, Kaiyan Li, Wang Ni, Guohua Zheng, Weining Xiong, Lingling Yi, Xihu Du, Yunhui Zhang, Zhi Li, Xiaoqiong Tan, Feng Liao, Shenglan Wang, Yijiang Huang, Xinjun Cai, Kai Liu, Shaojing Sheng, Yihui Fu, Shenghua Sun, Qiang Zhang, Jinweng Cai, Ye Ling, Pin Chen, Hong Luo, Lv Liu, Zhijun Liu, Yuling Tang, Yusheng Yan, Guiyan Mo, Long Wen, Yinqun Zhu, Du Fan +217 morewiley +1 more sourceTargeting Immunologic Pathways in Eosinophilic Granulomatosis With Polyangiitis: Translating Emerging Evidence Into Clinical Practice
Allergy, EarlyView.ABSTRACT
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and potentially life‐threatening systemic, inflammatory disease with multi‐organ manifestations, variable presentation and complex pathology. Multiple interconnected immunological pathways are implicated in EGPA pathology, including a type‐2 immune response driving predominantly ...Harold Wilson‐Morkeh, Lior Seluk, Philipp Bosch, Carolina Aguiar, Jens Thiel, Bernhard Hellmich, Michael E. Wechsler, Salman Siddiqui +7 morewiley +1 more sourceDelayed fatal neurotoxicity in post CAR-T cell therapy for multiple myeloma, a case report. [PDF]
Leuk Res RepKhoudari H, Shoaib A, Nashatizadeh M, Ahmed N, Lutfi F, Mushtaq M, Shune L, Singh A, Abhyankar S, McGuirk J, Abdelhakim H. +10 moreeuropepmc +1 more sourceNon-ICANS neurotoxicities CD19-directed CAR T-cell therapy and the emergence of movement and neurocognitive treatment-emergent adverse events: a case report. [PDF]
Front ImmunolSchroeder T, Chitadze G, Dargvainiene J, Martens T, Gebauer N, Frimmel J, Brüggemann M, Valerius T, Schub N, Baldus CD, Pott C, Leypoldt F, Stürner K, Stölzel F. +13 moreeuropepmc +1 more source
